FAQ

Frequently Asked Questions (FAQ)

1. What is the core mechanism of action behind DECALCIFIL ?

DECALCIFIL  utilizes a proprietary transdermal matrix that facilitates rapid bio-permeation of specialized citrate formulations through the skin barrier. Once absorbed, it targets labile, ectopic calcium deposits in soft tissues and vascular walls through selective chelation, accelerating natural clearance without mechanical disruption.

2. Does the technology affect structural bone mineral density (BMD)?

No. DECALCIFIL  is engineered with high tissue stewardship and target specificity. It acts exclusively on pathologically accessible, non-crystalline ectopic calcium burden, leaving structural hydroxyapatite within healthy bone tissue completely intact.

3. How fast is the systemic uptake, and how was it verified?

Transdermal uptake is ultra-fast. Human in vivo testing validated by Gas Chromatography-Mass Spectrometry (GC-MS) showed a +37.5% increase in systemic citrate response within 10 minutes post-application, without requiring micro-needling, iontophoresis, or physical acceleration devices.

4. What is the current Intellectual Property (IP) status?

Global exclusivity is secured through an international application filed under the WIPO Patent Cooperation Treaty (PCT) Priority Date: March 2025 (OSIM Deposit). This provides a clean, worldwide framework for national phase entries and exclusive regional or global licensing.

5. What commercial engagement models are available?

As an IP-focused spin-off, DECALCIFIL Innovations is open to global out-licensing agreements, co-development partnerships, or outright acquisition (M&A) by qualified pharmaceutical and biotech partners.